Maria Laura Bisegna

Pubblicazioni

Titolo Pubblicato in Anno
INTEGRATION OF CD200, CD43 AND ROR1 IN MULTIPARAMETER FLOW CYTOMETRY (MFC) ROUTINE PANELS FOR THE DIFFERENTIAL DIAGNOSIS OF B-CELL LYMPHOPROLIFERATIVE DISORDERS (B-LPDS) MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES 2025
Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with Ruxolitinib ONCOLOGY AND THERAPY 2025
A novel complex mutation in the exon 9 of CALR gene: p.E381fs*52 (gagg_CCTCTTTGCCTC) CURRENT RESEARCH IN TRANSLATIONAL MEDICINE 2025
T-cell Receptor (TCR)-Vβ Repertoire Flow Cytometry for T-cell Lymphoproliferative Disorder: a Retrospective Analysis of a Single-Center Real-Life Laboratory Experience MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES 2025
CD99 expression in acute myeloid leukemia with FLT3 internal tandem duplications (FLT3-ITDmut -AML): a flow-cytometric marker for an accurate diagnostic workup LEUKEMIA & LYMPHOMA 2025
Baseline, Drug‐Related and Persistent Anemia and/or Thrombocytopenia Predict Responses and Prognosis in Myelofibrosis Patients Treated With Ruxolitinib HEMATOLOGICAL ONCOLOGY 2025
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation EUROPEAN JOURNAL OF HAEMATOLOGY 2024
Ropeginterferon alfa-2b treatment in a young patient with multi-refractory polycythemia vera and double JAK2 gene mutation: a case report FRONTIERS IN ONCOLOGY 2024
Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia JOURNAL OF CLINICAL MEDICINE 2024
Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety EXPERT OPINION ON DRUG SAFETY 2024
Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors EXPERT OPINION ON PHARMACOTHERAPY 2024
Response Rates and Transplantation Impact in Patients with Relapsed Acute Promyelocytic Leukemia CANCERS 2024
NG2 molecule expression in acute lymphoblastic leukemia B cells: a flow-cytometric marker for the rapid identification of KMT2A gene rearrangements MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES 2024
CD146 MOLECULE EXPRESSION IN B CELLS ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALLs): A FLOW- CYTOMETRIC MARKER FOR AN ACCURATE DIAGNOSTIC WORK-UP MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES 2024
CD146 MOLECULE EXPRESSION IN B CELLS ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALLs): A FLOW- CYTOMETRIC MARKER FOR AN ACCURATE DIAGNOSTIC WORK-UP MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES 2024
Understanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in Chronic myeloid leukemia (CML) EXPERT REVIEW OF HEMATOLOGY 2024
Management of Chronic Myeloid Leukemia Patients in Later Lines: The Role of Ponatinib and New Compounds CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2023
Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients EXPERT REVIEW OF HEMATOLOGY 2022
Trapianto di cellule staminali Ematologia Smart, Edizioni Idelson Gnocchi 1908 2022
Diagnostica di laboratorio e strumentale Ematologia Smart, Edizioni Idelson Gnocchi 1908 2022

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma